ATAI News and Press, ATAI Life Sciences N.V. From 10/06/23

NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit being ...

A recently published study has found that more than 80% of psychiatrists positively view the use of psychedelic substances in treating a range of mental-health conditions. For the study, researchers from different institutions including Case Western Reserve University, Harvard Medical School an...

VLS-01, a proprietary oral transmucosal film (OTF) formulation of DMT, was well-tolerated with a favorable safety profile Pharmacokinetic and pharmacodynamic data confirmed systemic delivery of DMT via the oral, transmucosal route at levels comparable to those achieved with IV administr...

2023-09-29 10:00:00 ET More on psychedelic drugs Atai Life Sciences: RL-007, Targeting Schizophrenia Subpopulation With No FDA Approved Therapies With ecstasy a potential PTSD therapy, psychedelic treatments could take off Psychedelic Stocks = Super-Risky Biote...

Massachusetts-based healthcare provider Enthea has revealed that it is now offering psychedelic-assisted therapy coverage in employee healthcare plans nationwide . The provider was in the news last year when soap company Dr. Bronners announced that it would be offering psychedelic-assisted the...

2023-09-26 13:17:43 ET More on psychedelic drug development Atai Life Sciences: RL-007, Targeting Schizophrenia Subpopulation With No FDA Approved Therapies Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets. COMPASS: The Landscape Is Changing Qui...

This June, America’s first-ever service center for psilocybin-assisted therapy opened in Oregon, marking both the state and country’s first definitive steps toward legalizing therapeutic psilocybin for the masses. Oregon is the first state in the country to offer psilocybin-rela...

2023-09-19 08:00:18 ET FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – September 19, 2023 – Depression is costing the economy $1 trillion in lost production every single year. Yet, a classical compound that even the FDA has twi...

2023-09-16 16:00:56 ET On Sept. 14, the Multidisciplinary Association for Psychedelic Studies ("MAPS") announced positive results on a second phase 3 trial for MDMA -- also known as ecstasy -- for post-traumatic stress disorder that were published in a scientific journal. The data in th...

Recent research investigating the interaction between psychedelics and opioids has found that using the two together to treat chronic pain may not be a good idea. Opioids have been the go-to treatment for pain disorders for a long time, but they have lost popularity over the past decade, especi...